Neomatrix

Executive Summary

Neomatrix is an Italian biotechnology company focused on developing next-generation personalized cancer vaccines. Founded in 2015 and headquartered in Milan, the company integrates a proprietary platform that combines tumor neoantigen identification, synthetic DNA vaccine design, and a potent delivery system to selectively eliminate tumor cells. Its approach is designed to work synergistically with immune checkpoint inhibitors, potentially offering a more effective and durable treatment for cancer patients. Currently in the pre-clinical stage, Neomatrix has not disclosed total funding or valuation, but its innovative platform positions it in the competitive landscape of personalized medicine and immuno-oncology. The company's strategy leverages its unique technology to address the urgent need for tailored cancer therapies, with a focus on speed and efficacy.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Efficacy Data Readout70% success
• Q4 2026Partnership or Licensing Deal with Pharma40% success
• Q1 2027Series A Funding Round60% success